The company has raised $57.2m since it was founded in September 2009. Gen-Probe and all other existing investors including OrbiMed Advisors, New Enterprise Associates and TPG Biotech invested in the round.
Roka develops and commercialises products developed through molecular technologies for the industrial markets.